Estrogens modulate the density of opioid receptors in selected brain areas; however, it is not clear whether they exert such an effect directly on the cells which express the opioid receptors. Therefore, we analyzed the binding of [3H]-diprenorphine in human neuroblastoma cells stably transfected with the estrogen receptor cDNA (SK-ER3 cell line). A 16-hour exposure of these cells with 1 nM 17β-estradiol induces a progressive morphological differentiation which appears clearly established 6 days after the suspension of the treatment. The binding of [3H]-diprenorphine was then measured immediately after the exposure to 17β-estradiol (16 h) as well as 6 days later. The results shows that the number of opioid receptors in SK-ER3 cells is unaffected at 16 h but appears significantly reduced at 6 days. This effect is blocked by the estrogen antagonist ICI-182780, and is coincident to a decrease of the inhibitory effect of morphine on cyclic AMP accumulation. Binding experiments performed using selective ligands suggest that the µ subclass of opioid receptors is down-regulated by estradiol in SK-ER3 cells.

Keywords:
Gonadal steroids, Opiate peptides, Opiate receptors, Neuroblastoma, Development, Molecular neuroendocrinology
1.
McEwen B: Steroid hormones are multifunctional messengers to the brain. Trends Endocrinol Metab 1991;1:62–67.
2.
Ferreira A, Caceres A: Estrogen-enhanced neurite growth. Evidence for a selective induction of tau and stable microtubules. J Neurosci 1991;11:392–400.
3.
Frankfurt M, Gould E, Woolley CS, McEwen BS: Gonadal steroids modify dendritic spine density in ventromedial, hypothalamic neurons. A Golgi study in the adult rat. Neuroendocrinology 1990;51:530–535.
4.
Gibson DA, Vernadakis A: Response of chick cerebellum in culture to L-dopa and estradiol. Life Sci 1975;15:639–643.
5.
Wise PM, Scarbrough K, Weiland NG, Larson GH: Diurnal pattern of proopiomelanocortin gene expression in the arcuate nucleus of proestrus, ovariectomized, and steroid-treated rats: A possible role in cyclic luteinizing hormone secretion. Mol Endocrinol 1990;4:886–892.
6.
Piva F, Limonta P, Dondi D, Pimpinelli F, Martini L, Maggi R: Effects of steroids on the brain opioid systems. J Steroid Biochem Mol Biol 1995;53:343–348.
7.
Maggi R, Dondi D, Rovati GE, Martini L, Piva F, Limonta P: Binding characteristics of hypothalamic mu opioid receptors throughout the estrous cycle in the rat. Neuroendocrinology 1993;8:366–372.
8.
Limonta P, Dondi D, Maggi R, Piva F: Testosterone and postnatal ontogenesis of hypothalamic µ ([3H]dihydromorphine) opioid receptors in the rat. Dev Brain Res 1991;62:131–136.
9.
Dondi D, Maggi R, Panerai AE, Piva F, Limonta P: Hypothalamic opiatergic tone during pregnancy, parturition and lactation in the rat. Neuroendocrinology 1991;53:460–466.
10.
Hammer RP Jr, Mateo AR, Bridges RS: Hormonal regulation of medial preoptic mu-opiate receptor density before and after parturition. Neuroendocrinology 1992;56:38–45.
11.
Wilkinson M, Brawer JR, Wilkinson DA: Gonadal steroid-induced modification of opiate binding sites in anterior hypothalamus of female rats. Biol Reprod 1985;32:501–506.
12.
Weiland NG, Wise PM: Estrogen and progesterone regulate opiate receptor density in multiple brain regions. Endocrinology 1990;126:804–808.
13.
Dondi D, Limonta P, Maggi R, Piva F: Effects of ovarian hormones on brain opioid binding sites in castrated female rats. Am J Physiol 1992;263:E507–E511.
14.
Maggi R, Martini L, Piva F: Effect of ovariectomy on the binding characteristics of hypothalamic mu opioid receptors in the rat. Endocr Regul 1994;28:171–178.
15.
Brown LL, Pasi S, Etgen AM: Estrogen regulation of µ opioid receptor density in hypothalamic premammillary nuclei. Brain Res 1996;742:347–351.
16.
Mogil J, Sternberg W, Kest B, Marek P, Liebeskind J: Sex differences in the antagonism of swim stress-induced analgesia: Effects of gonadectomy and estrogen replacement. Pain 1993;53:17–25.
17.
Crain S: Spinal cord tissue culture models for analyses of opioid analgesia, tolerance and plasticity. NIDA Res Monogr 1984;54:260–292.
18.
Crain S, Shen K: Ultra-low concentrations of naloxone selectivity antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic treatment. Proc Natl Acad Sci USA 1995;92:10540–10544.
19.
Nomikos G, Spyraki C, Kazandjian A, Sfikakis A: Estrogen treatment to ovariectomized rats modifies morphine-induced behavior. Pharmacol Biochem Behav 1987;27:611–617.
20.
Ratka A, Simpkins J: A modulatory role for luteinizing hormone-releasing hormone in nociceptive responses of female rats. Endocrinology 1990;127:667–673.
21.
Ratka A, Simpkins J: Effects of estradiol and progesterone on the sensitivity to pain and on morphine-induced antinociception in female rats. Horm Behav 1991;25:217–228.
22.
Pahlman S, Mamaeva S, Meyerson G, Mattsson ME, Bjelfman C, Ortoft E, Hammerling U: Human neuroblastoma cells in culture: A model for neuronal cell differentiation and function. Acta Physiol Scand Suppl 1990;592:25–37.
23.
Yu CV, Sadée W: Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells. J Pharmacol Exp Ther 1988;245:350–355.
24.
Ma ZQ, Spreafico E, Pollio G, Santagati S, Conti E, Cattaneo E, Maggi A: Activated estrogen receptor mediates growth arrest and differentiation of a neuroblastoma cell line. Proc Natl Acad Sci USA 1993;90:3740–3744.
25.
Ma ZQ, Santagati S, Patrone C, Pollio G, Vegeto E, Maggi A: Insulin-like growth factors activate estrogen receptor to control the growth and differentiation of the human neuroblastoma cell line SK-ER3. Mol Endocrinol 1994;8:910–918.
26.
Santagati S, Ma ZQ, Ferrarini C, Pollio G, Maggi A: Expression of early genes in estrogen-induced phenotypic conversion of neuroblastoma cells. J Neuroendocrinol 1995;7:875–879.
27.
Agrati P, Garnier M, Patrone C, Pollio G, Santagati S, Vegeto E, Maggi A: SK-ER3 neuroblastoma cells as a model for the study of estrogen influence on neural cells. Brain Res Bull 1997;44:519–523.
28.
Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS: Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978;38:3751–3757.
29.
Polastron J, Mur M, Mazarguil H, Puget A, Meunier J-C, Jauzac P: SK-N-BE: A human neuroblastoma cell line containing two subtypes of δ-opioid receptors. J Neurochem 1994;62:898–906.
30.
Palazzi E, Ceppi E, Guglielmetti F, Catozzi L, Amoroso D, Groppetti A: Biochemical evidence of functional interaction between µ- and δ-opioid receptors in SK-N-BE neuroblastoma cell line. J Neurochem 1996;67:138–144.
31.
Wolleman M: Recent developments in the research of opioid receptor subtype molecular characterization. J Neurochem 1990;54:1095–1101.
32.
Maggi R, Pimpinelli F, Martini L, Piva F: Characterization of functional opioid delta receptors in a luteinizing hormone-releasing hormone producing neuronal cell line. Endocrinology 1995;136:289–295.
33.
Cone RI, Lameh J, Sadée W: Rapid agonist-induced loss of 125I-β-endorphin opioid receptor sites in NG108-15, but not SK-N-SH neuroblastoma cells. Life Sci 1991;49:PL147–PL152.
34.
Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the pinciple of protein-dye binding. Anal Biochem 1976;72:248–254.
35.
Rovati GE, Rodbard D, Munson PJ: DESIGN: Computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments. I. Homologous and heterologous binding to one classes of sites. Anal Biochem 1988;174:636–649.
36.
Munson PJ, Rodbard D: LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107:220–239.
37.
Maggi R, Rovati GE: MacEllipse, a graphical aid to the problem of the joint confidence region: A practical example for ligand binding experiments. Pharmacol Res 1993;28:1–8.
38.
Leslie FM: Methods used for the study of opioid receptors. Pharmacol Rev 1987;39:197–249.
39.
Pasternak GW, Wood PJ: Multiple mu opiate receptors. Life Sci 1986;38:1889–1898.
40.
Maggi R, Pimpinelli F, Casulari LA, Piva F, Martini L: Antiprogestins inhibit the binding of opioids to µ receptors in nervous membrane preparations. Eur J Pharmacol 1996;301:169–177.
41.
Schwarz S, Pohl P: Steroid and opioid receptors. J Steroid Biochem Mol Biol 1994;48:391–402.
42.
Kuramoto T, Werrbach-Perez K, Perez-Polo J, Haber B: Membrane properties of a human neuroblastoma. II. Effects of differentiation. J Neurosci Res 1981;6:441–449.
43.
Reynolds C, Perez-Polo J: Induction of neurite outgrowth in the IMR-32 human neuroblastoma cell line by nerve growth factor. J Neurosci Res 1981;6:319–325.
44.
Zadina JE, Harrison LM, Ge LJ, Kastin AJ, Chang SL: Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells. J Pharmacol Exp Ther 1994;270:1086–1096.
45.
Yu CV, Hochhaus G, Chang F-S, Richards ML, Bourne HR, Sadée W: Differentiation of human neuroblastoma cells: Marked potentiation of prostaglandin E-stimulated accumulation of cyclic AMP by retinoic acid. J Neurochem 1988;51:1892–1899.
46.
Ratka A, Hochhaus G, Wissler RN, Simpkins JW: cAMP accumulation in opioid-sensitive SH-SY5Y neuroblastoma cells is modified by estradiol and progesterone. Mol Cell Endocrinol 1991;78:155–162.
47.
Kelly MJ, Loose MD, Ronnekleiv OK: Estrogen suppresses mu-opioid- and GABAB- mediated hyperpolarization of hypothalamic arcuate neurons. J Neurosci 1992;12:2745–2750.
48.
Quinones-Jenab V, Jenab S, Ogawa S, Inturrisi C, Pfaff DW: Estrogen regulation of µ opioid receptor mRNA in the forebrain of female rats. Mol Brain Res 1997;47:134–138.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.